[go: up one dir, main page]

MA38076A1 - Dérivés d'oxazolidin-2-one-pyrimidine - Google Patents

Dérivés d'oxazolidin-2-one-pyrimidine

Info

Publication number
MA38076A1
MA38076A1 MA38076A MA38076A MA38076A1 MA 38076 A1 MA38076 A1 MA 38076A1 MA 38076 A MA38076 A MA 38076A MA 38076 A MA38076 A MA 38076A MA 38076 A1 MA38076 A1 MA 38076A1
Authority
MA
Morocco
Prior art keywords
oxazolidin
pyrimidine derivatives
pi3k
phosphatidylinositol
kinase
Prior art date
Application number
MA38076A
Other languages
English (en)
Inventor
Heinrich Rueeger
Pascal Furet
Andreas Lerchner
Robin Alec Fairhurst
Frank Stephan Kalthoff
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA38076A1 publication Critical patent/MA38076A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés d'oxazolidin-2-one pyrimidine substitués qui agissent en tant qu'inhibiteurs de la pi3 (phosphatidylinositol-3-kinase), ainsi que leurs compositions pharmaceutiques, leurs procédés de production et leurs utilisations pour traiter des états, des maladies et des troubles dépendant de la pi3k.
MA38076A 2012-11-12 2013-11-11 Dérivés d'oxazolidin-2-one-pyrimidine MA38076A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261725113P 2012-11-12 2012-11-12
PCT/IB2013/060052 WO2014072956A1 (fr) 2012-11-12 2013-11-11 Dérivés d'oxazolidin-2-one-pyrimidine

Publications (1)

Publication Number Publication Date
MA38076A1 true MA38076A1 (fr) 2018-02-28

Family

ID=49667527

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38076A MA38076A1 (fr) 2012-11-12 2013-11-11 Dérivés d'oxazolidin-2-one-pyrimidine

Country Status (42)

Country Link
US (3) US9296733B2 (fr)
EP (2) EP2922848B1 (fr)
JP (1) JP6262245B2 (fr)
KR (1) KR102153763B1 (fr)
CN (1) CN104718204B (fr)
AP (1) AP2015008347A0 (fr)
AR (1) AR093408A1 (fr)
AU (1) AU2013343022B2 (fr)
BR (1) BR112015010136A2 (fr)
CA (1) CA2890942C (fr)
CL (1) CL2015001202A1 (fr)
CO (1) CO7380758A2 (fr)
CR (1) CR20150248A (fr)
CU (1) CU24365B1 (fr)
CY (1) CY1119391T1 (fr)
DK (1) DK2922848T5 (fr)
EA (2) EA029714B1 (fr)
EC (1) ECSP15025093A (fr)
ES (1) ES2641820T3 (fr)
HR (1) HRP20171425T1 (fr)
HU (1) HUE034492T2 (fr)
IL (1) IL238239A (fr)
IN (1) IN2015DN02912A (fr)
JO (1) JO3334B1 (fr)
LT (1) LT2922848T (fr)
MA (1) MA38076A1 (fr)
MX (1) MX363436B (fr)
MY (1) MY174239A (fr)
NZ (1) NZ706591A (fr)
PE (1) PE20151006A1 (fr)
PH (1) PH12015501053A1 (fr)
PL (1) PL2922848T3 (fr)
PT (1) PT2922848T (fr)
RS (1) RS56336B1 (fr)
SG (1) SG11201503447QA (fr)
SI (1) SI2922848T1 (fr)
TN (1) TN2015000120A1 (fr)
TW (1) TWI608005B (fr)
UA (1) UA114001C2 (fr)
UY (1) UY35128A (fr)
WO (1) WO2014072956A1 (fr)
ZA (1) ZA201502175B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
PE20151939A1 (es) 2013-03-14 2016-01-08 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
KR20180081501A (ko) * 2015-09-24 2018-07-16 드렉셀유니버시티 진피 장애를 치료하거나 예방하는 신규한 조성물 및 방법
US10993947B2 (en) 2016-05-18 2021-05-04 Torqur Treatment of skin lesions
SG11201809652PA (en) * 2016-05-18 2018-12-28 Piqur Therapeutics Ag Treatment of skin lesions
TW201929861A (zh) 2017-11-06 2019-08-01 瑞士商諾華公司 包含㗁唑啶-2-酮-嘧啶衍生物之調配物
WO2019101853A1 (fr) 2017-11-23 2019-05-31 Piqur Therapeutics Ag Traitement de troubles cutanés
CA3192236A1 (fr) 2020-09-10 2022-03-17 Tony Lahoutte Fragment d'anticorps contre fap
WO2023203135A1 (fr) 2022-04-22 2023-10-26 Precirix N.V. Anticorps radiomarqué amélioré
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB581334A (en) 1943-09-29 1946-10-09 Francis Henry Swinden Curd New pyrimidine compounds
JPS4921149B1 (fr) 1970-12-28 1974-05-30
JPS4921148B1 (fr) 1970-12-28 1974-05-30
DE2341925A1 (de) 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
AT340933B (de) 1973-08-20 1978-01-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
US4994386A (en) 1987-07-13 1991-02-19 Pharmacia Diagnostics, Inc. Production of HBLV virus in the HSB-2 cell line
US4929726A (en) 1988-02-09 1990-05-29 Georgia State University Foundation, Inc. Novel diazines and their method of preparation
EP0330263A1 (fr) 1988-02-25 1989-08-30 Merck & Co. Inc. Pipérazinylalkylpyrimidines comme agents hypoglycémiques
GB9012311D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
DE69120221T2 (de) 1990-07-03 1996-11-21 Mitsui Petrochemical Ind Pyrimidin-verbindung und ihr pharmazeutisch annehmbares salz
AU692090B2 (en) 1995-04-13 1998-05-28 Taiho Pharmaceutical Co., Ltd. Novel 4,6-diarylpyrimidine derivatives and salts thereof
JP3734907B2 (ja) 1996-12-19 2006-01-11 富士写真フイルム株式会社 現像処理方法
DE69821633T2 (de) 1997-07-24 2004-12-16 Zenyaku Kogyo K.K. Heterozyklische verbindungen und antitumormittel, das diese als aktiven wirkstoff enthält
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
US6150362A (en) 1997-12-12 2000-11-21 Henkin; Jack Triazine angiogenesis inhibitors
DE69906397T2 (de) 1998-01-16 2004-02-19 F. Hoffmann-La Roche Ag Benzosulfonderivate
JP4533534B2 (ja) 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド グリコーゲンシンターゼキナーゼ３のインヒビター
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
AU768201B2 (en) 1999-01-22 2003-12-04 Amgen, Inc. Kinase inhibitors
US6495558B1 (en) 1999-01-22 2002-12-17 Amgen Inc. Kinase inhibitors
CA2376957A1 (fr) 1999-06-30 2001-01-04 Merck & Co., Inc. Composes inhibiteurs de la src kinase
CA2376951A1 (fr) 1999-06-30 2001-01-04 Peter J. Sinclair Composes inhibiteurs de la kinase src
CA2383546A1 (fr) 1999-06-30 2001-01-04 William H. Parsons Composes inhibiteurs de la src kinase
JP2003505384A (ja) 1999-07-15 2003-02-12 ファーマコピーア，インコーポレーティッド ブラジキニンｂ１受容体アンタゴニスト
JP2001089452A (ja) 1999-09-22 2001-04-03 Sankyo Co Ltd ピリミジン誘導体
US20030004174A9 (en) 2000-02-17 2003-01-02 Armistead David M. Kinase inhibitors
AU4262901A (en) 2000-03-29 2001-10-08 Cyclacel Ltd 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders
WO2001083456A1 (fr) 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Derives d'heteroaryle condenses
CN1440393A (zh) 2000-04-28 2003-09-03 田边制药株式会社 环状化合物
CA2409762A1 (fr) 2000-06-23 2002-01-03 Donald J.P. Pinto Inhibiteurs du facteur xa a substitution heteroaryl-phenyle
CN100506801C (zh) 2000-09-06 2009-07-01 诺华疫苗和诊断公司 糖元合成酶激酶3的抑制剂
ATE346064T1 (de) 2000-09-15 2006-12-15 Vertex Pharma Pyrazolverbindungen als protein-kinasehemmer
SE0004053D0 (sv) 2000-11-06 2000-11-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
ATE354573T1 (de) 2000-12-21 2007-03-15 Vertex Pharma ßPYRAZOLVERBINDUNGEN, DIE SICH ALS PROTEINKINASEINHIBITOREN EIGNENß
EP1363890A4 (fr) 2001-02-07 2009-06-10 Ore Pharmaceuticals Inc Composes de liaison au recepteur de la melanocortine-4 et procedes d'utilisation de tels composes
AU2002258400A1 (en) 2001-02-16 2002-08-28 Tularik Inc. Methods of using pyrimidine-based antiviral agents
EP1395561A1 (fr) 2001-05-25 2004-03-10 Boehringer Ingelheim Pharmaceuticals Inc. Composes de carbamate et d'oxamide inhibant la production de cytokine
HUP0402352A2 (hu) 2001-06-19 2005-02-28 Bristol-Myers Squibb Co. Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
US6603000B2 (en) 2001-07-11 2003-08-05 Boehringer Ingelheim Pharmaceuticals, Inc. Synthesis for heteroarylamine compounds
WO2003030909A1 (fr) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer
EP1485380B1 (fr) 2002-03-15 2010-05-19 Vertex Pharmaceuticals Incorporated Azolylaminoazines inhibitrices des proteines kinases
EP1485381B8 (fr) 2002-03-15 2010-05-12 Vertex Pharmaceuticals Incorporated Azolylaminoazines en tant qu'inhibiteurs de proteines kinases
US7091343B2 (en) 2002-03-15 2006-08-15 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
DE60314603T2 (de) 2002-03-15 2008-02-28 Vertex Pharmaceuticals Inc., Cambridge Zusammensetzungen brauchbar als protein-kinase-inhibitoren
WO2004000820A2 (fr) 2002-06-21 2003-12-31 Cellular Genomics, Inc. Monocycles aromatiques utilises comme modulateurs de la kinase
JP2006510597A (ja) 2002-09-27 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド 置換ピリミジン類
CA2501685A1 (fr) 2002-10-08 2004-04-22 Massachusetts Institute Of Technology Composes pour la modulation du transport du cholesterol
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
US7423148B2 (en) 2002-11-21 2008-09-09 Chiron Corporation Small molecule PI 3-kinase inhibitors and methods of their use
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
CN101468965A (zh) 2003-03-24 2009-07-01 默克公司 联芳基取代的6元杂环钠通道阻滞剂
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
US7763627B2 (en) 2003-04-09 2010-07-27 Exelixis, Inc. Tie-2 modulators and methods of use
WO2005009977A1 (fr) 2003-07-15 2005-02-03 Neurogen Corporation Analogues de pyrimidine-4-ylamine substitues constituant des ligands des recepteurs vanilloides
US7566712B2 (en) 2003-07-16 2009-07-28 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
AR045944A1 (es) * 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
ATE485824T1 (de) 2004-04-13 2010-11-15 Icagen Inc Polycyclische pyrimidine als kaliumionenkanal- modulatoren
GB0415365D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
MY145822A (en) 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
AU2005312048B2 (en) * 2004-11-30 2012-08-02 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
CN101080401A (zh) 2004-12-13 2007-11-28 神经能质公司 经取代的二芳基类似物
JP2008523152A (ja) 2004-12-13 2008-07-03 ニューロジェン・コーポレーション ピペラジニル−ピリジン類縁体
BRPI0519424B8 (pt) 2004-12-28 2021-05-25 Athenex Inc compostos, composição e uso dos ditos compostos para a preparação de um medicamento para prevenção ou tratamento de um distúrbio de proliferação celular ou infecção microbiana
CA2595205A1 (fr) 2005-01-19 2006-07-27 Neurogen Corporation Analogues de piperazinyl-pyridine a substitution heteroaryle
JP2008531537A (ja) 2005-02-25 2008-08-14 クドス ファーマシューティカルズ リミテッド 化合物
JP2008536950A (ja) 2005-04-18 2008-09-11 ニューロジェン・コーポレーション 置換ヘテロアリールのｃｂ１拮抗薬
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
US20110034454A1 (en) 2006-01-11 2011-02-10 Allan Paul Dishington Morpholino pyrimidine derivatives and their use in therapy
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
EP2012794B1 (fr) * 2006-04-13 2014-09-17 The Trustees of Columbia University in the City of New York Compositions et dispositifs intraluminaux permettant d'inhiber la stenose vasculaire
WO2008080937A1 (fr) 2006-12-28 2008-07-10 Basf Se Pyrimidines 2-substituées dans le cadre d'une thérapie
KR20090108124A (ko) 2007-02-06 2009-10-14 노파르티스 아게 Ｐｉ 3-키나제 억제제 및 그의 사용 방법
US7957951B2 (en) 2007-03-16 2011-06-07 Robert Bosch Gmbh Address translation system for use in a simulation environment
EP2074118A2 (fr) 2007-07-09 2009-07-01 AstraZeneca AB Derives de pyrimidine trisubstitues pour le traitement de maladies proliferatives
WO2009066084A1 (fr) 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2-morpholinopyrimidines et leur utilisation en tant qu'inhibiteurs de kinase pi3
WO2009109605A1 (fr) 2008-03-05 2009-09-11 Novartis Ag Utilisation de dérivés de la pyrimidine pour le traitement de maladies dépendantes d'egfr ou de maladies qui ont acquis une résistance à des agents qui ciblent les membres de la famille egfr
CA2925257C (fr) 2008-03-26 2019-04-30 Carlos Garcia-Echeverria 5-imidazoquinoleines et derives de pyrimidine en tant que modulateurs puissants de processus angiogeniques controles par vegf
US20110053907A1 (en) 2008-03-27 2011-03-03 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
TW200948362A (en) 2008-04-09 2009-12-01 Mitsubishi Tanabe Pharma Corp New compounds and their uses
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
RU2538683C2 (ru) 2008-10-31 2015-01-10 Новартис Аг КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (Р13К) И ИНГИБИТОРА mTOR
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010068863A2 (fr) 2008-12-12 2010-06-17 Cystic Fibrosis Foundation Therapeutics, Inc. Composés de pyrimidine et leurs procédés de fabrication et d'utilisation
JP5263304B2 (ja) 2009-02-06 2013-08-14 日本新薬株式会社 アミノピラジン誘導体及び医薬
JP5747440B2 (ja) 2009-02-06 2015-07-15 住友化学株式会社 ヒドラジド化合物及びその有害生物防除用途
CN108524505A (zh) 2009-03-13 2018-09-14 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
WO2010120994A2 (fr) 2009-04-17 2010-10-21 Wyeth Llc Composés d'uréido-aryl-pyrimidine et de carbamoylaryl-morpholino-pyrimidine, leur utilisation comme inhibiteurs de la kinase mtor et de la kinase pi-3, et leur synthèse
DK2432767T3 (da) 2009-05-19 2013-09-30 Dow Agrosciences Llc Forbindelser og fremgangsmåder til at kontrollere svampe
EP2451802A1 (fr) 2009-07-07 2012-05-16 Pathway Therapeutics, Inc. Pyrimidinyl et 1,3,5-triazinyl benzimidazoles et leur utilisation dans le traitement du cancer
AR077695A1 (es) 2009-08-04 2011-09-14 Schering Corp Derivados de pirimidina como inhibidores del factor ixa
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
JP2013504325A (ja) 2009-09-09 2013-02-07 アビラ セラピューティクス， インコーポレイテッド Ｐｉ３キナーゼインヒビターおよびその使用
JP5967827B2 (ja) 2009-12-09 2016-08-10 アジオス ファーマシューティカルズ， インコーポレイテッド Ｉｄｈ変異体をもつことを特徴とする癌治療用の治療的活性化合物
GB201004200D0 (en) 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
WO2011143160A2 (fr) 2010-05-10 2011-11-17 The Johns Hopkins University Inhibiteur métabolique contre des tumeurs ayant une mutation de l'idh
CN103097340B (zh) 2010-07-16 2018-03-16 安吉奥斯医药品有限公司 治疗活性组合物及其使用方法
RU2015150728A (ru) 2010-10-01 2019-01-15 Новартис Аг Способ получения пиримидиновых производных
SG2014012850A (en) 2010-10-18 2014-05-29 Cerenis Therapeutics Holding Sa Compounds, compositions and methods useful for cholesterol mobilisation
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
WO2012109423A1 (fr) 2011-02-11 2012-08-16 Dana-Farber Cancer Institute, Inc. Procédé d'inhibition de cellules tumorales d'hamartome
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CA2846272A1 (fr) 2011-09-01 2013-03-07 Novartis Ag Inhibiteur de pi3k s'utilisant dans le traitement du cancer des os ou pour prevenir la dissemination metastatique de cellules cancereuses primaires dans l'os
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
AU2012318874A1 (en) 2011-10-06 2014-05-15 Merck Sharp & Dohme Corp. 1,3-substituted azetidine PDE10 inhibitors
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
JP6381523B2 (ja) * 2012-05-16 2018-08-29 ノバルティス アーゲー Ｐｉ−３キナーゼ阻害剤の投与レジメン
BR112014030099A2 (pt) 2012-06-06 2017-06-27 Novartis Ag combinação de um inibidor 17-alfa-hidroxilase(c17,20-liase) e um inibidor pi-3 k específico para tratamento de uma doença de tumor
IN2015DN00528A (fr) 2012-08-16 2015-06-26 Novartis Ag
CN104736532B (zh) 2012-10-23 2017-04-05 诺华股份有限公司 改进的生产5‑(2,6‑二‑4‑吗啉‑4‑嘧啶)‑4‑三氟甲基吡啶‑2‑胺的方法
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
JP2016514124A (ja) 2013-03-14 2016-05-19 ノバルティス アーゲー 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
PE20151939A1 (es) 2013-03-14 2016-01-08 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
CN103483345B (zh) 2013-09-25 2016-07-06 中山大学 Pi3k激酶抑制剂、包含其的药物组合物及其应用
CN103694218B (zh) 2013-12-05 2016-04-27 中山大学 嘧啶化合物、pi3k抑制剂、包含pi3k抑制剂的药物组合物及应用

Also Published As

Publication number Publication date
DK2922848T5 (en) 2017-10-30
SG11201503447QA (en) 2015-05-28
US20190382399A1 (en) 2019-12-19
CY1119391T1 (el) 2018-02-14
HK1209108A1 (en) 2016-03-24
PT2922848T (pt) 2017-10-05
MX2015005914A (es) 2015-09-08
MY174239A (en) 2020-04-01
EP3199158A1 (fr) 2017-08-02
JP6262245B2 (ja) 2018-01-17
PE20151006A1 (es) 2015-07-04
US9296733B2 (en) 2016-03-29
KR20150082295A (ko) 2015-07-15
US20160168145A1 (en) 2016-06-16
TWI608005B (zh) 2017-12-11
EA201790289A1 (ru) 2017-06-30
AU2013343022B2 (en) 2015-08-20
UY35128A (es) 2014-06-30
CR20150248A (es) 2015-07-01
CU24365B1 (es) 2018-10-04
SI2922848T1 (sl) 2017-10-30
IL238239A (en) 2017-05-29
ECSP15025093A (es) 2019-03-29
CN104718204B (zh) 2017-11-28
EP3199158B1 (fr) 2019-04-17
EA027987B1 (ru) 2017-09-29
CN104718204A (zh) 2015-06-17
ZA201502175B (en) 2018-05-30
CO7380758A2 (es) 2015-09-10
CU20150050A7 (es) 2015-11-27
KR102153763B1 (ko) 2020-09-09
EA201590929A1 (ru) 2015-08-31
BR112015010136A2 (pt) 2017-07-11
HUE034492T2 (en) 2018-02-28
AU2013343022A1 (en) 2015-04-23
CA2890942C (fr) 2021-01-12
HRP20171425T1 (hr) 2017-11-17
PL2922848T3 (pl) 2017-12-29
US20140135330A1 (en) 2014-05-15
WO2014072956A1 (fr) 2014-05-15
CA2890942A1 (fr) 2014-05-15
TN2015000120A1 (en) 2016-06-29
NZ706591A (en) 2016-03-31
JO3334B1 (ar) 2019-03-13
DK2922848T3 (da) 2017-10-09
MX363436B (es) 2019-03-22
ES2641820T3 (es) 2017-11-14
EP2922848A1 (fr) 2015-09-30
PH12015501053B1 (en) 2015-07-27
RS56336B1 (sr) 2017-12-29
CL2015001202A1 (es) 2015-07-03
EA029714B1 (ru) 2018-05-31
TW201427974A (zh) 2014-07-16
LT2922848T (lt) 2017-09-25
EP2922848B1 (fr) 2017-06-28
AR093408A1 (es) 2015-06-03
US10202371B2 (en) 2019-02-12
IN2015DN02912A (fr) 2015-09-11
AP2015008347A0 (en) 2015-04-30
PH12015501053A1 (en) 2015-07-27
JP2015536974A (ja) 2015-12-24
UA114001C2 (xx) 2017-04-10

Similar Documents

Publication Publication Date Title
MA38076A1 (fr) Dérivés d'oxazolidin-2-one-pyrimidine
MA42376B1 (fr) Dérivés d'oxopyridine substitués
MA40240A (fr) Composés hétéroaryle d'inhibition de la kinase
MA44474B1 (fr) Inhibiteurs de la ferroportine
MA34969B1 (fr) Composes et compositions en tant qu inibiteurs de trk
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
PH12014501900A1 (en) Oxazolidin-2-one compounds and uses thereof as pi3ks inhibitors
MA35460B1 (fr) Composés et compositions en tant qu'inhibiteurs de kinase c-kit
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA47356B1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MA34968B1 (fr) Urées asymétriques et utilisations médicales de celles-ci
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA39171A1 (fr) Dérivés d'hydroxy formamide et leur utilisation
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA38925A1 (fr) Dérivés de phénylalanine substitués
MA38678A1 (fr) Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
MA37700B1 (fr) N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments
MA35894B1 (fr) Composés d'oxazolidine-2-one et utilisations de ceux-ci en tant qu'inhibiteurs des pi3k
FR3042191B1 (fr) Derives 1,4,8-triazaphenanthrene pour le traitement de maladies neurodegeneratives
MA38451A1 (fr) Benzoimidazol-2-ylpyrimidines modulatrices du récepteur de l'histamine h4
MA39719B1 (fr) Pyrazoles substitués par un trifluoromethyle en tant qu`inhibiteurs de la kallicréine plasmatique humaine
TN2014000340A1 (en) Oxazolidin- 2 -one compounds and uses thereof as pi3ks inhibitors
MA38838A1 (fr) Dérivés de pipéridinyl-indole et leur utilisation en tant qu'inhibiteurs du facteur b du complément
FR2985256B1 (fr) Derives piperazinyles pour le traitement de cancers
MA39118B1 (fr) Quinazoline-thf-amines utilisées en tant qu'inhibiteurs de la pde1